Cardioprotective effects of N-hydroxyguanidine PR5 in myocardial ischaemia and reperfusion in rats

Open Access
Publisher Website
Google Scholar
Abstract
The potential for the N‐hydroxyguanidine compound PR5 (N‐(3,4‐dimethoxy‐2‐chlorobenzylideneamino)‐N′‐hydroxyguanidine) as a cardioprotective agent in heart ischaemia and reperfusion injury was investigated using rat models. Administration of 1–10 mg kg−1 of PR5 5 min before 10 min of left coronary artery occlusion, followed by 20 min reperfusion, strongly inhibited reperfusion burst of arrhythmias and markedly improved the survival of the animals (e.g. ventricular fibrillation incidence 93 vs 43% (PP−1 of PR5, respectively). Administration of 3 mg kg−1 of PR5 1 min before reperfusion to rats subjected to 10 min occlusion, 20 min reperfusion was most effective in reducing arrhythmias and decreasing mortality (43 vs 0%, P−1 protein for ischaemic; P−1 PR5 were administered 1 min before reperfusion the increase was attenuated (MDA being 1.04±0.12; P−1 of PR5 (PBritish Journal of Pharmacology (1999) 128, 1089–1097; doi:10.1038/sj.bjp.0702887